- Home
- CTMX vs ORMP Comparison
CTMX vs ORMP Comparison
Compare CTMX & ORMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTMX
- ORMP
- Stock Information
- Founded
- CTMX 2008
- ORMP 2002
- Country
- CTMX United States
- ORMP United States
- Employees
- CTMX N/A
- ORMP N/A
- Industry
- CTMX Biotechnology: Pharmaceutical Preparations
- ORMP Biotechnology: Pharmaceutical Preparations
- Sector
- CTMX Health Care
- ORMP Health Care
- Exchange
- CTMX Nasdaq
- ORMP Nasdaq
- Market Cap
- CTMX 444.3M
- ORMP N/A
- IPO Year
- CTMX 2015
- ORMP N/A
- Fundamental
- Price
- CTMX $2.50
- ORMP $2.18
- Analyst Decision
- CTMX Strong Buy
- ORMP Hold
- Analyst Count
- CTMX 2
- ORMP 1
- Target Price
- CTMX $5.00
- ORMP N/A
- AVG Volume (30 Days)
- CTMX 2.6M
- ORMP 77.2K
- Earning Date
- CTMX 08-07-2025
- ORMP 08-15-2025
- Dividend Yield
- CTMX N/A
- ORMP N/A
- EPS Growth
- CTMX 128.27
- ORMP N/A
- EPS
- CTMX 0.49
- ORMP N/A
- Revenue
- CTMX $147,557,000.00
- ORMP $2,000,000.00
- Revenue This Year
- CTMX N/A
- ORMP N/A
- Revenue Next Year
- CTMX N/A
- ORMP N/A
- P/E Ratio
- CTMX $5.15
- ORMP N/A
- Revenue Growth
- CTMX 23.81
- ORMP 196.74
- 52 Week Low
- CTMX $0.40
- ORMP $1.82
- 52 Week High
- CTMX $3.10
- ORMP $3.09
- Technical
- Relative Strength Index (RSI)
- CTMX 57.13
- ORMP 49.72
- Support Level
- CTMX $2.15
- ORMP $2.10
- Resistance Level
- CTMX $2.44
- ORMP $2.25
- Average True Range (ATR)
- CTMX 0.22
- ORMP 0.09
- MACD
- CTMX -0.03
- ORMP 0.00
- Stochastic Oscillator
- CTMX 41.67
- ORMP 63.16
About CTMX CytomX Therapeutics Inc.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.